Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a joint injection of growth hormone and Platelet-Rich plasma offer a new path for arthritis relief?

NCT ID NCT06907121

Disease control Sponsor: Integrant Pty Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial is testing whether injecting a combination of growth hormone and platelet-rich plasma directly into the joint can improve pain, stiffness, and function in adults with knee or ankle arthritis that hasn't responded to usual treatments. Half of the 192 participants will receive the active injections, while the other half will get a saline placebo, with five injections given over a few weeks. The study measures success by looking for at least a 30% improvement in joint-specific scores at six months after the final injection, and also checks for structural changes on MRI. If it works, this approach could become a non-surgical option for people with resistant arthritis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intra-articular injections of recombinant human growth hormone (somatropin) combined with platelet-rich plasma (PRP)
What this could lead to
If successful, this could offer a non-surgical treatment option for people with knee or ankle arthritis that hasn't responded to standard care, potentially reducing pain and improving mobility.
What could go wrong
This is an early-phase trial, so the treatment may not prove more effective than placebo. Injections carry risks like pain, swelling, or infection, and results may not apply to all arthritis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 192 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria include: * Ankle/Knee arthritis resistant to treatment in GP clinic setting. * Radiographically confirmed cartilage injury with Kellgren-Lawrence grade 1-3 can be shown on MRI scan or weight bearing X-Ray within 6 months of study application. * Able to give informed consent to participate in a clinical trial. * Able to commit to attending a clinic for follow up. Exclusion Criteria: Known contraindications for ARTG registered somatropin from various manufacturers (Humatrope, Genotropin) have been used to guide the development of somatropin-related exclusion criteria. Exclusion criteria include: * A known hypersensitivity to any of the components of the product. * Cancer diagnosis or suspicion. * Resected or active tumour. * Skeletally immature (\<18 years of age or no radiographic evidence of closure of epiphyses). * Pregnancy/breastfeeding (participants of childbearing potential need negative pregnancy test in prior screening and agreed upon method of contraception throughout duration of study) * Active infection at the injection site. * Open soft tissue injury. * Metabolic disorders known to adversely affect the skeleton (e.g. renal osteodystrophy or hypercalcemia), other than primary osteoporosis or diabetes. * Over 70 years of age. * Unstable joint or maligned joint \> 5 degrees. * Severe osteoarthritis (Kellgren-Lawrence grade 4 on baseline imaging), including bone-on-bone joints with no detectable cartilage. * Known hypersensitivity to citrate or somatropin. * Unable to give informed consent. * Unable to commit to attend clinic for all follow ups.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis ankle are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis ankle Arthritis knee

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Integrant Office

    Potts Point, New South Wales, 2011, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.